---
+--------------------------------------------------------------------------------------------------------------------+
| Primary Hero (imageslide, title fs 48px, titlefont ringside, description fs 24px, herosize large, textcolor white, |
| overlay dark, ctanumber one) |
+--------------------------------------------------------------------------------------------------------------------+
| # **Results of the First Phase 3 Study of Retatrutide in Participants With Type 2 Diabetes (TRANSCEND-T2D-1)** |
+--------------------------------------------------------------------------------------------------------------------+
| Author: Harpreet Singh Bajaj, MD, MPH |
| |
| Endocrinologist, LMC Diabetes & Endocrinology (Toronto)\ |
| Chair, Endocrine and Metabolic Research, Centricity Canada\ |
| Past Chair, Clinical Practice Guidelines, Diabetes Canada |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| [/content/dam/ewi-claude-demo-site-8/default-image.jpg](/content/dam/ewi-claude-demo-site-8/default-image.jpg) |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| \[Enter Video Path] |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| true |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| center center |
+--------------------------------------------------------------------------------------------------------------------+
| center center |
+--------------------------------------------------------------------------------------------------------------------+
| desktopPlacement-center |
+--------------------------------------------------------------------------------------------------------------------+
| mobilePlacement-center |
+--------------------------------------------------------------------------------------------------------------------+
+----------------------------------------------+
| Section Metadata (content section container) |
+-----------------------+----------------------+
| text | pdf-page-001 |
+-----------------------+----------------------+
| backgroundOption | color |
+-----------------------+----------------------+
| backgroundColor | background-none |
+-----------------------+----------------------+
| textColor | auto |
+-----------------------+----------------------+
| additionalPadding | none |
+-----------------------+----------------------+
| additionalMargin | none |
+-----------------------+----------------------+
---
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+------------------------------------------------------------------------------------------------------+
| Text Component (alignment left, title fs 48px, description fs 20px, footnote fs 14px, ctanumber one) |
+------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------+
| ## Disclosures |
+------------------------------------------------------------------------------------------------------+
| **Speaking/Consulting Honoraria** : |
| |
| - Novo Nordisk |
| - Eli Lilly and Company |
| |
| **Trial/Research Support** : |
| |
| - Amgen |
| - AstraZeneca |
| - Boehringer Ingelheim |
| - Ceapro |
| - Eli Lilly and Company |
| - Gilead |
| - Janssen |
| - Kowa Pharmaceuticals |
| - Madrigal Pharmaceuticals |
| - Merck KGaA |
| - Novo Nordisk |
| - Pfizer |
| - Sanofi |
| - Tricida |
+------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+----------------------------------------------+
| Section Metadata (content section container) |
+-----------------------+----------------------+
| text | pdf-page-002 |
+-----------------------+----------------------+
| backgroundOption | color |
+-----------------------+----------------------+
| backgroundColor | background-none |
+-----------------------+----------------------+
| textColor | auto |
+-----------------------+----------------------+
| additionalPadding | none |
+-----------------------+----------------------+
| additionalMargin | none |
+-----------------------+----------------------+
---
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, ctastyle primary, ctacolor |
| light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| **Retatrutide: Novel Triple Receptor Agonist** |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+-------------------------------------------------+
| Image Block (none, desc bg none, title fs 24px) |
+-------------------------------------------------+
| ![][image0] |
+-------------------------------------------------+
| |
+-------------------------------------------------+
| |
+-------------------------------------------------+
| |
+-------------------------------------------------+
| |
+-------------------------------------------------+
| |
+-------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------------------------------------------------------------------+
| Text Component (alignment left, ctanumber one, ctatype button, ctacolor light, ctastyle primary, ctatarget sametab, |
| ctaexitinterstitial select, ctaplacement vertical, ctatype button two, ctacolor light two, ctastyle primary two, |
| ctatarget sametab two, ctaexitinterstitial select two) |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| 1\. Coskun T, et al. Cell Metab. 2022;34:1234-1247.e9. 2. Urva S, et al. Lancet. 2022;400:1869-1881. GCGR=glucagon |
| receptor; GIP=glucose-dependent insulinotropic polypeptide; GIPR=GIP receptor; GLP-1R=glucagon-like peptide-1 |
| receptor; SC=subcutaneous. |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, description fs 20px, |
| ctastyle primary, ctacolor light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------+
| **Retatrutide Phase 3 Program Across Obesity & Complications** |
+-----------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------+
+-------------------------------------------------+
| Image Block (none, desc bg none, title fs 24px) |
+-------------------------------------------------+
| ![][image1] |
+-------------------------------------------------+
| |
+-------------------------------------------------+
| |
+-------------------------------------------------+
| |
+-------------------------------------------------+
| |
+-------------------------------------------------+
| |
+-------------------------------------------------+
+-------------------------------------------------+
| Image Block (none, desc bg none, title fs 24px) |
+-------------------------------------------------+
| ![][image2] |
+-------------------------------------------------+
| |
+-------------------------------------------------+
| |
+-------------------------------------------------+
| |
+-------------------------------------------------+
| |
+-------------------------------------------------+
| |
+-------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+----------------------------------------------+
| Section Metadata (content section container) |
+-----------------------+----------------------+
| text | pdf-page-002 |
+-----------------------+----------------------+
| backgroundOption | color |
+-----------------------+----------------------+
| backgroundColor | background-muted |
+-----------------------+----------------------+
| textColor | auto |
+-----------------------+----------------------+
| additionalPadding | none |
+-----------------------+----------------------+
| additionalMargin | none |
+-----------------------+----------------------+
---
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, ctastyle primary, ctacolor |
| light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| **TRANSCEND-T2D-1 Study Design** |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+-------------------------------------------------+
| Image Block (none, desc bg none, title fs 24px) |
+-------------------------------------------------+
| ![][image3] |
+-------------------------------------------------+
| |
+-------------------------------------------------+
| |
+-------------------------------------------------+
| true |
+-------------------------------------------------+
| |
+-------------------------------------------------+
| |
+-------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+----------------------------------------------------------------------------------------------------------------------+
| Text Component (alignment left, ctanumber one, ctatype button, ctacolor light, ctastyle primary, ctatarget sametab, |
| ctaexitinterstitial select, ctaplacement vertical, ctatype button two, ctacolor light two, ctastyle primary two, |
| ctatarget sametab two, ctaexitinterstitial select two) |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| aInadequate glycemic control with diet and exercise alone. Note: Temporary dose reduction for intolerable |
| GI symptoms can be initiated for a 4-week period only during dose escalation (the first 20 weeks of the study) and |
| should be followed by a dose re-escalation attempt. https\://clinicaltrials.gov/study/NCT06354660 (Accessed May 19, |
| 2026). BMI=body mass index; GI=gastrointestinal; HbA1c=glycated hemoglobin; PBO=placebo; QW=once weekly; |
| RETA=retatrutide; T2D=type 2 diabetes |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+----------------------------------------------+
| Section Metadata (content section container) |
+-----------------------+----------------------+
| text | pdf-page-002 |
+-----------------------+----------------------+
| backgroundOption | color |
+-----------------------+----------------------+
| backgroundColor | background-none |
+-----------------------+----------------------+
| textColor | auto |
+-----------------------+----------------------+
| additionalPadding | none |
+-----------------------+----------------------+
| additionalMargin | none |
+-----------------------+----------------------+
---
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-------------------------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, description fs 20px, ctastyle primary, |
| ctacolor light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-------------------------------------------------------------------------------------------------------------------------------------+
| |
+-------------------------------------------------------------------------------------------------------------------------------------+
| **Primary objective**: To demonstrate the superiority of retatrutide (4 mg, 9 mg, 12 mg) vs. placebo in glycemic control at Week 40 |
+-------------------------------------------------------------------------------------------------------------------------------------+
| |
+-------------------------------------------------------------------------------------------------------------------------------------+
| |
+-------------------------------------------------------------------------------------------------------------------------------------+
| |
+-------------------------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, description fs 20px, |
| ctastyle primary, ctacolor light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------+
| **Primary Endpoint** |
+-----------------------------------------------------------------------------------------------------------------+
| Change from baseline in HbA1c at Week 40 |
+-----------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, description fs 20px, |
| ctastyle primary, ctacolor light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------+
| **Key Secondary Endpointsa (at Week 40)** |
+-----------------------------------------------------------------------------------------------------------------+
| - Incidence of participant with **HbA1c of <7.0%, ≤6.5%, and <5.7%b.** |
| - Change from baseline in **fasting serum glucoseb.** |
| - Change from baseline in **body weight**. |
| - Incidence of participant reaching **weight reduction** of ≥5%; ≥10%; and ≥15%b. |
| - Incidence of participant with HbA1c ≤6.5% and reaching ≥10% body weight reduction from baseline. |
| - Percent change from baseline in lipid parameters (**non–HDL-C and triglycerides**)b. |
| - Change **in systolic blood pressureb** |
+-----------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------------------------------------------------------------------+
| Text Component (alignment left, ctanumber one, ctatype button, ctacolor light, ctastyle primary, ctatarget sametab, |
| ctaexitinterstitial select, ctaplacement vertical, ctatype button two, ctacolor light two, ctastyle primary two, |
| ctatarget sametab two, ctaexitinterstitial select two) |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| ᵃStrongly controlled for type I error. ᵇFor retatrutide 9 and 12 mg ONLY.\ |
| *HbA1c=glycated hemoglobin; HDL-C=high-density lipoprotein cholesterol.* |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+----------------------------------------------+
| Section Metadata (content section container) |
+-----------------------+----------------------+
| text | pdf-page-002 |
+-----------------------+----------------------+
| backgroundOption | color |
+-----------------------+----------------------+
| backgroundColor | background-muted |
+-----------------------+----------------------+
| textColor | auto |
+-----------------------+----------------------+
| additionalPadding | none |
+-----------------------+----------------------+
| additionalMargin | none |
+-----------------------+----------------------+
---
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, description fs 20px, |
| ctastyle primary, ctacolor light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-------------------------------------------------------------------------------------------------------------------+
| |
+-------------------------------------------------------------------------------------------------------------------+
| **Statistical Methods and Estimands** |
+-------------------------------------------------------------------------------------------------------------------+
| What is the treatment difference in mean change in HbA1c from baseline at Week 40 between retatrutide 4 mg, 9 mg, |
| and/or 12 mg doses vs. placebo in individuals who meet eligibility criteria… |
+-------------------------------------------------------------------------------------------------------------------+
| |
+-------------------------------------------------------------------------------------------------------------------+
| |
+-------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, description fs 20px, |
| ctastyle primary, ctacolor light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------+
| **Efficacy Estimand** |
+-----------------------------------------------------------------------------------------------------------------+
| …assuming the following intercurrent events did not occur |
| |
| - **Permanent discontinuation** of study intervention. |
| - Initiation of additional **anti-hyperglycemic medicationsa** |
| |
| All randomized participants (ITT) MMRM or ANCOVA with missing endpoints imputed |
+-----------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, description fs 20px, |
| ctastyle primary, ctacolor light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------+
| **Treatment Regimen Estimand** |
+-----------------------------------------------------------------------------------------------------------------+
| …regardless of adherence to study intervention or initiation of additional anti-hyperglycemic medications |
| |
| All randomized participants (ITT) ANCOVA with missing endpoints imputed |
+-----------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------------------------------------------------------------------+
| Text Component (alignment left, ctanumber one, ctatype button, ctacolor light, ctastyle primary, ctatarget sametab, |
| ctaexitinterstitial select, ctaplacement vertical, ctatype button two, ctacolor light two, ctastyle primary two, |
| ctatarget sametab two, ctaexitinterstitial select two) |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| ᵃAdditional AHMs refers to any AHM used for >14 days.\ |
| *ANCOVA=analysis of covariance; HbA1c=glycated hemoglobin; ITT=intent-to-treat; MMRM=mixed model for repeated |
| measures.* |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+----------------------------------------------+
| Section Metadata (content section container) |
+-----------------------+----------------------+
| text | pdf-page-002 |
+-----------------------+----------------------+
| backgroundOption | color |
+-----------------------+----------------------+
| backgroundColor | background-none |
+-----------------------+----------------------+
| textColor | auto |
+-----------------------+----------------------+
| additionalPadding | none |
+-----------------------+----------------------+
| additionalMargin | none |
+-----------------------+----------------------+
---
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, ctastyle primary, ctacolor |
| light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| **Baseline Demographics** |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+------------------------------------------------------------------------------------------------------------------+
| Image Block (none, desc bg none, title fs 24px) |
+------------------------------------------------------------------------------------------------------------------+
| ![][image4] |
+------------------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------------------+
| a>90 days prior to Visit 1. Notes: Data are shown as mean (SD) unless stated otherwise. Data from all |
| randomized participants with non-missing data. BMI=body mass index; FSG=fasting serum glucose; HbA1c=glycated |
| hemoglobin; N=number of participants; PBO=placebo; RETA=retatrutide; SD=standard deviation; T2D=type 2 diabetes. |
+------------------------------------------------------------------------------------------------------------------+
| true |
+------------------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------------------------------------------------------------------+
| Text Component (alignment left, ctanumber one, ctatype button, ctacolor light, ctastyle primary, ctatarget sametab, |
| ctaexitinterstitial select, ctaplacement vertical, ctatype button two, ctacolor light two, ctastyle primary two, |
| ctatarget sametab two, ctaexitinterstitial select two) |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
+----------------------------------------------+
| Section Metadata (content section container) |
+-----------------------+----------------------+
| text | pdf-page-002 |
+-----------------------+----------------------+
| backgroundOption | color |
+-----------------------+----------------------+
| backgroundColor | background-muted |
+-----------------------+----------------------+
| textColor | auto |
+-----------------------+----------------------+
| additionalPadding | none |
+-----------------------+----------------------+
| additionalMargin | none |
+-----------------------+----------------------+
---
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, ctastyle primary, ctacolor |
| light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| **Participant Disposition** |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------------------------------------------------------------------+
| Image Block (none, desc bg none, title fs 24px) |
+---------------------------------------------------------------------------------------------------------------------+
| ![][image5] |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| Notes: Study completion is defined as completing both the 40-week treatment period and the safety follow-up period, |
| regardless of completion of study intervention. If participants discontinue the study during the treatment period, |
| they also discontinue the study intervention, either earlier or at the same time. PBO=placebo; RETA=retatrutide. |
+---------------------------------------------------------------------------------------------------------------------+
| true |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+----------------------------------------------+
| Section Metadata (content section container) |
+-----------------------+----------------------+
| text | pdf-page-002 |
+-----------------------+----------------------+
| backgroundOption | color |
+-----------------------+----------------------+
| backgroundColor | background-none |
+-----------------------+----------------------+
| textColor | auto |
+-----------------------+----------------------+
| additionalPadding | none |
+-----------------------+----------------------+
| additionalMargin | none |
+-----------------------+----------------------+
---
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, ctastyle primary, ctacolor |
| light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| **Primary Endpoint: HbA1c Over 40 Weeks With Retatrutide** |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Image Block (none, desc bg none, title fs 24px) |
+-----------------------------------------------------------------------------------------------------------------------+
| ![][image6] |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| \*\*\*p<0.001. p-values are for MBE change difference vs. PBO. Notes: Data presented are MBE ± SE, and MBE difference |
| (95% CI). EE analysis was conducted using MMRM. TRE analysis was conducted using ANCOVA. Data are from all randomized |
| participants. ANCOVA=analysis of covariance; CI=confidence interval; EE=efficacy estimand; HbA1c=glycated hemoglobin; |
| MBE=model-based estimate; MMRM=mixed model for repeated measures; N=number of participants; PBO=placebo; |
| RETA=retatrutide; SE=standard error; TRE=treatment regimen estimand. |
+-----------------------------------------------------------------------------------------------------------------------+
| true |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+----------------------------------------------+
| Section Metadata (content section container) |
+-----------------------+----------------------+
| text | pdf-page-002 |
+-----------------------+----------------------+
| backgroundOption | color |
+-----------------------+----------------------+
| backgroundColor | background-muted |
+-----------------------+----------------------+
| textColor | auto |
+-----------------------+----------------------+
| additionalPadding | none |
+-----------------------+----------------------+
| additionalMargin | none |
+-----------------------+----------------------+
---
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, ctastyle primary, ctacolor |
| light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| **Indirect Comparison of Change in HbA1c From Baseline in Similar Phase 3 Studies (Efficacy Estimand)** |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+----------------------------------------------------------------------------------------------------------------------+
| Image Block (none, desc bg none, title fs 24px) |
+----------------------------------------------------------------------------------------------------------------------+
| ![][image7] |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| Notes: This indirect comparison is for illustrative purposes and is not intended to draw conclusions based on the |
| results of different studies. In SUSTAIN-1, semaglutide was a once-weekly subcutaneous injection. 1. Sorli C, et al. |
| Lancet Diabetes Endocrinol. 2017;5:251-260. 2. Rosenstock J, et al. Lancet. 2021;398:143-155. GCG=glucagon; |
| GIP=glucose-dependent insulinotropic polypeptide; GLP-1=glucagon-like peptide-1; HbA1c=glycated hemoglobin; |
| PBO=placebo; RA=receptor agonist; RETA=retatrutide; Sema=semaglutide; TZP=tirzepatide. |
+----------------------------------------------------------------------------------------------------------------------+
| true |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+----------------------------------------------+
| Section Metadata (content section container) |
+-----------------------+----------------------+
| text | pdf-page-002 |
+-----------------------+----------------------+
| backgroundOption | color |
+-----------------------+----------------------+
| backgroundColor | background-none |
+-----------------------+----------------------+
| textColor | auto |
+-----------------------+----------------------+
| additionalPadding | none |
+-----------------------+----------------------+
| additionalMargin | none |
+-----------------------+----------------------+
---
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, ctastyle primary, ctacolor |
| light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| **Proportion of Participants Reaching HbA1c Targets at Week 40 With Retatrutide** |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Image Block (none, desc bg none, title fs 24px) |
+-----------------------------------------------------------------------------------------------------------------------+
| ![][image8] |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| RETA vs. PBO: \*\*\*p<0.001. p-values are for risk difference vs. PBO. Data are from all randomized participants. |
| Notes: Data presented are MBE ± SE. HbA1c target <5.7% was not controlled for type I error for the RETA 4 mg arm. |
| HbA1c=glycated hemoglobin; MBE=model-based estimate; N=number of participants with non-missing value at the specified |
| time point; PBO=placebo; RETA=retatrutide; SE=standard error |
+-----------------------------------------------------------------------------------------------------------------------+
| true |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+----------------------------------------------+
| Section Metadata (content section container) |
+-----------------------+----------------------+
| text | pdf-page-002 |
+-----------------------+----------------------+
| backgroundOption | color |
+-----------------------+----------------------+
| backgroundColor | background-muted |
+-----------------------+----------------------+
| textColor | auto |
+-----------------------+----------------------+
| additionalPadding | none |
+-----------------------+----------------------+
| additionalMargin | none |
+-----------------------+----------------------+
---
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, ctastyle primary, ctacolor |
| light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| **Fasting Serum Glucose Over Time With Retatrutide vs. PBO** |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Image Block (none, desc bg none, title fs 24px) |
+-----------------------------------------------------------------------------------------------------------------------+
| ![asas][image9] |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| RETA vs. PBO: \*\*\*p<0.001. p-values are for MBE change difference vs. PBO. Notes: Data presented are MBE ± SE, and |
| MBE difference (95% CI). EE analysis was conducted using MMRM. The comparison of RETA 4 mg vs. PBO was not controlled |
| for type I error. CI=confidence interval; EE=efficacy estimand; MBE=model-based estimate; MMRM=mixed model for |
| repeated measures; N=number of participants; PBO=placebo; RETA=retatrutide; SE=standard error. |
+-----------------------------------------------------------------------------------------------------------------------+
| true |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+----------------------------------------------+
| Section Metadata (content section container) |
+-----------------------+----------------------+
| text | pdf-page-002 |
+-----------------------+----------------------+
| backgroundOption | color |
+-----------------------+----------------------+
| backgroundColor | background-none |
+-----------------------+----------------------+
| textColor | auto |
+-----------------------+----------------------+
| additionalPadding | none |
+-----------------------+----------------------+
| additionalMargin | none |
+-----------------------+----------------------+
---
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, ctastyle primary, ctacolor |
| light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| **Percent Change From Baseline in Body Weight With Retatrutide** |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+----------------------------------------------------------------------------------------------------------------------+
| Image Block (none, desc bg none, title fs 24px) |
+----------------------------------------------------------------------------------------------------------------------+
| ![asas][image10] |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| RETA vs. PBO: \*\*\*p<0.001. p-values are for MBE change difference vs. PBO. Notes: Data presented are MBE ± SE, and |
| MBE difference (95% CI). EE analysis was conducted using MMRM. TRE analysis was conducted using ANCOVA. Data are |
| fromall randomized participants. ANCOVA=analysis of covariance; CI=confidence interval; EE=efficacy estimand; |
| MBE=model-based estimate; MMRM=mixed model for repeated measures; N=number of participants; PBO=placebo; |
| RETA=retatrutide; SE=standard error; TRE=treatment regimen estimand |
+----------------------------------------------------------------------------------------------------------------------+
| true |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+----------------------------------------------+
| Section Metadata (content section container) |
+-----------------------+----------------------+
| text | pdf-page-002 |
+-----------------------+----------------------+
| backgroundOption | color |
+-----------------------+----------------------+
| backgroundColor | background-muted |
+-----------------------+----------------------+
| textColor | auto |
+-----------------------+----------------------+
| additionalPadding | none |
+-----------------------+----------------------+
| additionalMargin | none |
+-----------------------+----------------------+
---
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, ctastyle primary, ctacolor |
| light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| **Indirect Comparison of Percent Change in Body Weight From Baseline in Similar Phase 3 Studies (Efficacy Estimand)** |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Image Block (none, desc bg none, title fs 24px) |
+-----------------------------------------------------------------------------------------------------------------------+
| ![asas][image11] |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| Notes: This indirect comparison is for illustrative purposes and is not intended to draw conclusions based on the |
| results of different studies. Percent weight change data for SUSTAIN-1 were estimated from literature-reported weight |
| change (kg). In SUSTAIN-1, semaglutide was a once-weekly subcutaneous injection. 1. Sorli C, et al. Lancet Diabetes |
| Endocrinol. 2017;5:251-260. 2. Rosenstock J, et al. Lancet. 2021;398:143-155. BMI=body mass index; GCG=glucagon; |
| GIP=glucose-dependent insulinotropic polypeptide; GLP-1=glucagon-like peptide-1; PBO=placebo; RA=receptor agonist; |
| RETA=retatrutide; Sema=semaglutide; TZP=tirzepatide |
+-----------------------------------------------------------------------------------------------------------------------+
| true |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+----------------------------------------------+
| Section Metadata (content section container) |
+-----------------------+----------------------+
| text | pdf-page-002 |
+-----------------------+----------------------+
| backgroundOption | color |
+-----------------------+----------------------+
| backgroundColor | background-none |
+-----------------------+----------------------+
| textColor | auto |
+-----------------------+----------------------+
| additionalPadding | none |
+-----------------------+----------------------+
| additionalMargin | none |
+-----------------------+----------------------+
---
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, ctastyle primary, ctacolor |
| light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| **Proportion of Participants Reaching Weight Reduction Thresholds at Week 40 With Retatrutide** |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+--------------------------------------------------------------------------------------------------------------------+
| Image Block (none, desc bg none, title fs 24px) |
+--------------------------------------------------------------------------------------------------------------------+
| ![asas][image12] |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| \*\*p<0.01, \*\*\*p<0.001 vs. PBO. Notes: Data presented are MBE ± SE. EE analysis from logistic regression model. |
| The weight reduction thresholds of ≥20% and ≥25% were not controlled for type I error for any RETA dose and the |
| threshold of ≥15% was also not controlled for type I error in the RETA 4 mg arm. EE=efficacy estimand; |
| MBE=model-based estimate; N=number of participants; PBO=placebo; RETA=retatrutide; SE=standard error. |
+--------------------------------------------------------------------------------------------------------------------+
| true |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+----------------------------------------------+
| Section Metadata (content section container) |
+-----------------------+----------------------+
| text | pdf-page-002 |
+-----------------------+----------------------+
| backgroundOption | color |
+-----------------------+----------------------+
| backgroundColor | background-muted |
+-----------------------+----------------------+
| textColor | auto |
+-----------------------+----------------------+
| additionalPadding | none |
+-----------------------+----------------------+
| additionalMargin | none |
+-----------------------+----------------------+
---
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, ctastyle primary, ctacolor |
| light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| **Proportion of Participants Reaching HbA1c ≤6.5% AND ≥10.0% Weight Reduction at Week 40 With Retatrutide** |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+--------------------------------------------------------------------------------------------------------------------+
| Image Block (none, desc bg none, title fs 24px) |
+--------------------------------------------------------------------------------------------------------------------+
| ![TRANSCEND\_T2D\_1\_dv\_036761\_14][image13] |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| \*\*\*p<0.001 vs. PBO. Notes: Data presented are MBE ± SE. EE analysis from logistic regression model. EE=efficacy |
| estimand; HbA1c=glycated hemoglobin; MBE=model-based estimate; N=number of participants; PBO=placebo; |
| RETA=retatrutide; SE=standard error |
+--------------------------------------------------------------------------------------------------------------------+
| true |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+----------------------------------------------+
| Section Metadata (content section container) |
+-----------------------+----------------------+
| text | pdf-page-002 |
+-----------------------+----------------------+
| backgroundOption | color |
+-----------------------+----------------------+
| backgroundColor | background-none |
+-----------------------+----------------------+
| textColor | auto |
+-----------------------+----------------------+
| additionalPadding | none |
+-----------------------+----------------------+
| additionalMargin | none |
+-----------------------+----------------------+
---
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, ctastyle primary, ctacolor |
| light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| **Percentage Change in Lipid and Blood Pressure Parameters From Baseline to Week 40 With Retatrutide** |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Image Block (none, desc bg none, title fs 24px) |
+-----------------------------------------------------------------------------------------------------------------------+
| ![asas][image14] |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| RETA vs. PBO: \*p<0.05, \*\*p<0.01, \*\*\*p<0.001. p-values are for MBE percent change difference. Notes: Data |
| presented are MBE. EE analysis was conducted using MMRM. The comparisons of RETA 9 mg and 12 mg vs. PBO for |
| triglycerides and non–HDL-c were controlled for type I error. No other endpoints or dose comparisons were included in |
| the multiplicity adjustment procedure. For systolic BP, RETA 9 mg and 12 mg adjusted for multiplicity. All other |
| doses across systolic and diastolic BP not adjusted for multiplicity. BP=blood pressure; CV=coefficient of variation; |
| EE=efficacy estimand; HDL-c=high-density lipoprotein calculated; LDL-c=low-density lipoprotein calculated; |
| MBE=model-based estimate; MMRM=mixed model for repeated measures; N=number of participants; PBO=placebo; |
| RETA=retatrutide |
+-----------------------------------------------------------------------------------------------------------------------+
| true |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| **Efficacy Estimated** |
+-----------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+----------------------------------------------+
| Section Metadata (content section container) |
+-----------------------+----------------------+
| text | pdf-page-002 |
+-----------------------+----------------------+
| backgroundOption | color |
+-----------------------+----------------------+
| backgroundColor | background-none |
+-----------------------+----------------------+
| textColor | auto |
+-----------------------+----------------------+
| additionalPadding | none |
+-----------------------+----------------------+
| additionalMargin | none |
+-----------------------+----------------------+
---
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, ctastyle primary, ctacolor |
| light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| **Overview of Adverse Events** |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+-------------------------------------------------+
| Image Block (none, desc bg none, title fs 24px) |
+-------------------------------------------------+
| ![asas][image15] |
+-------------------------------------------------+
| |
+-------------------------------------------------+
| |
+-------------------------------------------------+
| true |
+-------------------------------------------------+
| |
+-------------------------------------------------+
| |
+-------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Text Component (alignment left, description fs 20px, ctanumber one, ctatype button, ctacolor light, ctastyle primary, |
| ctatarget sametab, ctaexitinterstitial select, ctaplacement vertical, ctatype button two, ctacolor light two, |
| ctastyle primary two, ctatarget sametab two, ctaexitinterstitial select two) |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| **aDeaths are also included as serious AEs and discontinuation due to AEs. bMACE (confirmed by |
| Clinical Endpoint Committee) includes: deaths due to cardiovascular cause, myocardial infarction, hospitalization for |
| unstable angina, hospitalization/urgent visit for heart failure, coronary interventions (such as CABG or PCI), and |
| cerebrovascular events, including cerebrovascular accident (stroke) and TIA. Notes: Data are reported for the safety |
| data points set. Safety population defined as all participants who were randomly assigned a study intervention and |
| who received ≥1 dose of double-blind study intervention. MedDRA Version 28.1 (September 2025). AE=adverse event; |
| CABG=coronary artery bypass graft; MACE=major adverse cardiovascular event; MedDRA=Medical Dictionary for Regulatory |
| Activities; n=number of participants in the specified category; N=all randomly assigned participants who took ≥1 dose |
| of study intervention; PBO=placebo; PCI=percutaneous coronary intervention; RETA=retatrutide; TEAE=treatment-emergent |
| AE; TIA=transient ischemic attack.** |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+----------------------------------------------+
| Section Metadata (content section container) |
+-----------------------+----------------------+
| text | pdf-page-002 |
+-----------------------+----------------------+
| backgroundOption | color |
+-----------------------+----------------------+
| backgroundColor | background-none |
+-----------------------+----------------------+
| textColor | auto |
+-----------------------+----------------------+
| additionalPadding | none |
+-----------------------+----------------------+
| additionalMargin | none |
+-----------------------+----------------------+
---
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, ctastyle primary, ctacolor |
| light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| **Adverse Events Occurring in ≥5% of Participants in Any Group** |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+-------------------------------------------------+
| Image Block (none, desc bg none, title fs 24px) |
+-------------------------------------------------+
| ![asas][image16] |
+-------------------------------------------------+
| |
+-------------------------------------------------+
| |
+-------------------------------------------------+
| true |
+-------------------------------------------------+
| |
+-------------------------------------------------+
| |
+-------------------------------------------------+
+----------------------------------------------------------------------------------------------------------------------+
| Text Component (alignment left, ctanumber one, ctatype button, ctacolor light, ctastyle primary, ctatarget sametab, |
| ctaexitinterstitial select, ctaplacement vertical, ctatype button two, ctacolor light two, ctastyle primary two, |
| ctatarget sametab two, ctaexitinterstitial select two) |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| Notes: Data are reported for the safety data points set. Safety population defined as all participants who were |
| randomly assigned a study intervention and who received ≥1 dose of double-blind study intervention. MedDRA Version |
| 28\.1 (September 2025). AE=adverse event; MedDRA=Medical Dictionary for Regulatory Activities; n=number of |
| participants in the specified category; N=all randomly assigned participants who took ≥1 dose of study intervention; |
| PBO=placebo; RETA=retatrutide. |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+----------------------------------------------+
| Section Metadata (content section container) |
+-----------------------+----------------------+
| text | pdf-page-002 |
+-----------------------+----------------------+
| backgroundOption | color |
+-----------------------+----------------------+
| backgroundColor | background-muted |
+-----------------------+----------------------+
| textColor | auto |
+-----------------------+----------------------+
| additionalPadding | none |
+-----------------------+----------------------+
| additionalMargin | none |
+-----------------------+----------------------+
---
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, ctastyle primary, ctacolor |
| light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| **Adverse Events Leading to Treatment Discontinuation Reported by Preferred Term** |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+-------------------------------------------------+
| Image Block (none, desc bg none, title fs 24px) |
+-------------------------------------------------+
| ![asas][image17] |
+-------------------------------------------------+
| |
+-------------------------------------------------+
| |
+-------------------------------------------------+
| true |
+-------------------------------------------------+
| |
+-------------------------------------------------+
| |
+-------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+----------------------------------------------------------------------------------------------------------------------+
| Text Component (alignment left, ctanumber one, ctatype button, ctacolor light, ctastyle primary, ctatarget sametab, |
| ctaexitinterstitial select, ctaplacement vertical, ctatype button two, ctacolor light two, ctastyle primary two, |
| ctatarget sametab two, ctaexitinterstitial select two) |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| Notes: Data are reported for the safety data points set. Safety population defined as all participants who were |
| randomly assigned a study intervention and who received ≥1 dose of double-blind study intervention. MedDRA Version |
| 28\.1 (September 2025).\ |
| AE=adverse event; GI=gastrointestinal; MedDRA=Medical Dictionary for Regulatory Activities; n=number of participants |
| in the specified category; N=all randomly assigned participants who took ≥1 dose of study intervention; PBO=placebo; |
| RETA=retatrutide |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+----------------------------------------------+
| Section Metadata (content section container) |
+-----------------------+----------------------+
| text | pdf-page-002 |
+-----------------------+----------------------+
| backgroundOption | color |
+-----------------------+----------------------+
| backgroundColor | background-none |
+-----------------------+----------------------+
| textColor | auto |
+-----------------------+----------------------+
| additionalPadding | none |
+-----------------------+----------------------+
| additionalMargin | none |
+-----------------------+----------------------+
---
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 36px, titlestyle ringside, ctastyle primary, ctacolor |
| light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| **TRANSCEND-T2D-1: Retatrutide Efficacy Summary** |
+-----------------------------------------------------------------------------------------------------------------------+
| Retatrutide met the primary and all key secondary endpoints for both estimands |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Icon Card (column configuration 2 col, background color none) |
+------+--------------+------------+--------------------------------+-----------------------+------+------+------+------+
| | ![][image18] | **Superior | icon-card-item, title-fs-28px, | - HbA1c improvement | | | | |
| | | glycemic | ctanumber-one, ctatype-button, | up to -1.9% | | | | |
| | | control | ctacolor-light, | - Up to 85% reaching | | | | |
| | | vs. | ctastyle-primary, | HbA1c ≤6.5%, and up | | | | |
| | | placebo** | ctaselection-link, | to 46% | | | | |
| | | | ctatarget-sametab, | near-normoglycemia | | | | |
| | | | ctaexitinterstitial-select, | (<5.7%) | | | | |
| | | | ctatype-button-two, | | | | | |
| | | | ctacolor-light-two, | | | | | |
| | | | ctastyle-primary-two, | | | | | |
| | | | ctaselection-link-two, | | | | | |
| | | | ctatarget-sametab-two, | | | | | |
| | | | ctaexitinterstitial-select-two | | | | | |
+------+--------------+------------+--------------------------------+-----------------------+------+------+------+------+
| | ![][image19] | **Superior | icon-card-item, title-fs-28px, | with up to -16.8% | | | | |
| | | weight | ctanumber-one, ctatype-button, | weight reduction (-17 | | | | |
| | | reduction | ctacolor-light, | kg/-37 lb) | | | | |
| | | vs. | ctastyle-primary, | | | | | |
| | | placebo** | ctaselection-link, | | | | | |
| | | | ctatarget-sametab, | | | | | |
| | | | ctaexitinterstitial-select, | | | | | |
| | | | ctatype-button-two, | | | | | |
| | | | ctacolor-light-two, | | | | | |
| | | | ctastyle-primary-two, | | | | | |
| | | | ctaselection-link-two, | | | | | |
| | | | ctatarget-sametab-two, | | | | | |
| | | | ctaexitinterstitial-select-two | | | | | |
+------+--------------+------------+--------------------------------+-----------------------+------+------+------+------+
+--------------------------------------------------------------------------------------------------------------------------------------+
| Icon Card (column configuration 2 col, background color none) |
+------+--------------------------+---------------------+--------------------------------+-----------------+------+------+------+------+
| | ![][image20] | **Up to 68% of | icon-card-item, title-fs-28px, | | | | | |
| | | retatrutide-treated | ctanumber-one, ctatype-button, | | | | | |
| | | participants | ctacolor-light, | | | | | |
| | | reached HbA1c of | ctastyle-primary, | | | | | |
| | | ≤6.5% and ≥10% | ctaselection-link, | | | | | |
| | | weight reduction** | ctatarget-sametab, | | | | | |
| | | | ctaexitinterstitial-select, | | | | | |
| | | | ctatype-button-two, | | | | | |
| | | | ctacolor-light-two, | | | | | |
| | | | ctastyle-primary-two, | | | | | |
| | | | ctaselection-link-two, | | | | | |
| | | | ctatarget-sametab-two, | | | | | |
| | | | ctaexitinterstitial-select-two | | | | | |
+------+--------------------------+---------------------+--------------------------------+-----------------+------+------+------+------+
| | ![dv-036761-22][image21] | **Clinically | icon-card-item, title-fs-28px, | in | | | | |
| | | meaningful | ctanumber-one, ctatype-button, | cardiometabolic | | | | |
| | | improvements** | ctacolor-light, | markers: | | | | |
| | | | ctastyle-primary, | Systolic blood | | | | |
| | | | ctaselection-link, | pressure, | | | | |
| | | | ctatarget-sametab, | non–HDL-C, and | | | | |
| | | | ctaexitinterstitial-select, | triglycerides | | | | |
| | | | ctatype-button-two, | | | | | |
| | | | ctacolor-light-two, | | | | | |
| | | | ctastyle-primary-two, | | | | | |
| | | | ctaselection-link-two, | | | | | |
| | | | ctatarget-sametab-two, | | | | | |
| | | | ctaexitinterstitial-select-two | | | | | |
+------+--------------------------+---------------------+--------------------------------+-----------------+------+------+------+------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------------------------------------------------------------------+
| Text Component (alignment left, ctanumber one, ctatype button, ctacolor light, ctastyle primary, ctatarget sametab, |
| ctaexitinterstitial select, ctaplacement vertical, ctatype button two, ctacolor light two, ctastyle primary two, |
| ctatarget sametab two, ctaexitinterstitial select two) |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| *HbA1c=glycated hemoglobin; HDL-C=high-density lipoprotein cholesterol.* |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+----------------------------------------------+
| Section Metadata (content section container) |
+-----------------------+----------------------+
| text | pdf-page-002 |
+-----------------------+----------------------+
| backgroundOption | color |
+-----------------------+----------------------+
| backgroundColor | background-none |
+-----------------------+----------------------+
| textColor | auto |
+-----------------------+----------------------+
| additionalPadding | none |
+-----------------------+----------------------+
| additionalMargin | none |
+-----------------------+----------------------+
---
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, ctastyle primary, ctacolor |
| light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| **TRANSCEND-T2D-1: Retatrutide Safety Summary** |
+-----------------------------------------------------------------------------------------------------------------------+
| Overall safety profile generally consistent with GLP-1 RA−based therapy |
| |
| - The most common AEs with retatrutide were gastrointestinal, mostly mild to moderate, and occurred primarily during |
| dose escalation. |
| - Treatment discontinuation due to an AE was 2-5%. |
| - Treatment discontinuation due to a GI AE was 0-3%. |
| - No new safety signals were observed. |
| - No severe hypoglycemia was reported. |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------------------------------------------------------------------+
| Text Component (alignment left, ctanumber one, ctatype button, ctacolor light, ctastyle primary, ctatarget sametab, |
| ctaexitinterstitial select, ctaplacement vertical, ctatype button two, ctacolor light two, ctastyle primary two, |
| ctatarget sametab two, ctaexitinterstitial select two) |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| *AE=adverse event; GI=gastrointestinal; GLP-1=glucagon-like peptide-1; RA=receptor agonist.* |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 32px, titlestyle ringside, ctastyle primary, ctacolor |
| light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| **The LANCET** |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+----------------------------------+
| Image Block (none, desc bg none) |
+----------------------------------+
| ![][image22] |
+----------------------------------+
| |
+----------------------------------+
| |
+----------------------------------+
| true |
+----------------------------------+
| |
+----------------------------------+
| |
+----------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Metadata |
+--------------------------+------------------------------------------------------------------------------------------------------------------------------------+
| title | Results of the First Phase 3 Study of Retatrutide in Participants with Type 2 Diabetes (TRANSCEND-T2D-1) |
+--------------------------+------------------------------------------------------------------------------------------------------------------------------------+
| published-time | 2026-06-16T17:30:48.162Z |
+--------------------------+------------------------------------------------------------------------------------------------------------------------------------+
| content-page-ref | VP84TiyHhVTFKjPLxr27HIFCdEey2PgLwbCe6\_upEMN63izOXQHlbLZCD\_hEAa7BBLXE-RLHrLcTQovDNWIg2Wi5zgBbAAXfdpzD1fYpBGWhWwaa0WTdNbNYxziF-WWR |
+--------------------------+------------------------------------------------------------------------------------------------------------------------------------+
| json-ld | { "@context": "https\://schema.org", "@type": "MedicalWebPage", "@id": |
| | "https\://lilly.com/hcp/congresses/ada-2026/dv-036761-rt#webpage", "name": "TRANSCEND-T2D-1: First Phase 3 Study of Retatrutide |
| | in Type 2 Diabetes", "url": "https\://lilly.com/hcp/congresses/ada-2026/dv-036761-rt", "description": "Official Eli Lilly HCP |
| | congress presentation of TRANSCEND-T2D-1 Phase 3 results, presented at the American Diabetes Association Scientific Sessions 2026 |
| | by Harpreet Singh Bajaj, MD, MPH", "keywords": "retatrutide, TRANSCEND-T2D-1, type 2 diabetes, glycemic control, HbA1c, weight |
| | loss, triple hormone receptor agonist, GIP receptor agonist, GLP-1 receptor agonist, glucagon receptor agonist, once-weekly |
| | injection, fasting serum glucose, cardiometabolic outcomes, blood pressure reduction, triglyceride reduction, Eli Lilly, phase 3 |
| | clinical trial, ADA 2026, randomized controlled trial", "abstract": "PRIMARY ENDPOINT (Week 40): Change in HbA1c from baseline — |
| | Efficacy estimand: PBO −0.8%, RETA 4 mg −1.7%, RETA 9 mg −2.0%, RETA 12 mg −1.9% (all p<0.001 vs PBO). Treatment regimen estimand: |
| | PBO −0.9%, RETA 4 mg −1.7%, RETA 9 mg −1.9%, RETA 12 mg −1.9%. HbA1c values at Week 40: PBO 7.2%, RETA 4 mg 6.2%, RETA 9 mg 5.9%, |
| | RETA 12 mg 6.0%. HbA1c TARGETS: ≤6.5% achieved — RETA 4 mg \~60%, RETA 9 mg \~85%, RETA 12 mg \~85% vs PBO; <5.7% |
| | (near-normoglycemia) up to 46%. FASTING SERUM GLUCOSE (Week 40): Baseline 136.1 mg/dL. Changes: RETA 4 mg −39.7 mg/dL, RETA 9 mg |
| | −40.1 mg/dL, RETA 12 mg −40.3 mg/dL vs PBO (all p<0.001). BODY WEIGHT (Week 40): Baseline 96.9 kg (213.6 lbs). Efficacy estimand: |
| | PBO −2.5%, RETA 4 mg −11.5%, RETA 9 mg −15.5%, RETA 12 mg −16.8% (up to 16.6 kg / 36.6 lbs lost). Weight thresholds (RETA 12 mg vs |
| | PBO): ≥5% 89.9% vs 28.5%; ≥10% 75.1% vs 7.9%; ≥15% 55.0% vs 2.9%; ≥20% 31.3% vs 1.8%; ≥25% 15.9% vs 0.1%. DUAL ENDPOINT: HbA1c |
| | ≤6.5% AND ≥10% weight reduction — RETA 4 mg 44.3%, RETA 9 mg 65.0%, RETA 12 mg 67.8% vs PBO 2.9% (all p<0.001). CARDIOMETABOLIC |
| | (Week 40, efficacy estimand): Triglycerides: RETA 4 mg −28.1%, RETA 9 mg −29.8%, RETA 12 mg −39.6% vs PBO −3.4%. Non-HDL-C: RETA 4 |
| | mg −15.6%, RETA 9 mg −19.8%, RETA 12 mg −16.5% vs PBO −4.8%. SBP: RETA 4 mg −5.1, RETA 9 mg −5.8, RETA 12 mg −6.4 mmHg vs PBO −1.6 |
| | mmHg. SAFETY: TEAEs \~63–64% in RETA arms vs 57.5% PBO. Most common AEs: nausea (26.5%), diarrhea (22.8%), vomiting (17.6%) — |
| | predominantly mild-moderate during dose escalation. Discontinuation due to AEs: RETA 4 mg 2.2%, RETA 9 mg 4.5%, RETA 12 mg 5.1%. |
| | No severe hypoglycemia reported. DISPOSITION: N=930 screened; N=537 randomized (100% exposed). Completed treatment: PBO 92.5%, |
| | RETA 4 mg 94.8%, RETA 9 mg 90.2%, RETA 12 mg 87.5%.", "author": { "@type": "Person", "@id": |
| | "https\://lilly.com/hcp/congresses/ada-2026/dv-036761-rt#author-bajaj", "name": "Harpreet Singh Bajaj", "honorificSuffix": |
| | "MD, MPH", "affiliation": { "@type": "Organization", "@id": |
| | "https\://lilly.com/hcp/congresses/ada-2026/dv-036761-rt#lmc", "name": "LMC Diabetes & Endocrinology", "address": { |
| | "@type": "PostalAddress", "addressLocality": "Toronto", "addressCountry": "CA" } }, "jobTitle": |
| | "Endocrinologist; Chair, Endocrine and Metabolic Research, Centricity Canada" }, "mainEntity": { "@type": "MedicalStudy", |
| | "@id": "https\://lilly.com/hcp/congresses/ada-2026/dv-036761-rt", "name": "TRANSCEND-T2D-1: Phase 3 Study of Retatrutide in |
| | Adults with Type 2 Diabetes", "alternateName": \[ "TRANSCEND-T2D-1", "Retatrutide Phase 3 Type 2 Diabetes Study" |
| | ], "description": "A randomized, double-blind, placebo-controlled, parallel-group, Phase 3 trial evaluating once-weekly |
| | subcutaneous retatrutide (4 mg, 9 mg, 12 mg) versus placebo in 537 adults with type 2 diabetes (T2D). Key inclusion criteria: |
| | HbA1c ≥7.0% to ≤9.5% at screening, BMI ≥23 kg/m², stable weight (≤5 kg change) for ≥90 days prior to screening, naïve to insulin |
| | therapy, no anti-hyperglycemic agents for ≥90 days prior to screening. Mean baseline HbA1c 7.9%, mean baseline BMI 35.8 kg/m², |
| | mean baseline body weight 96.9 kg (213.6 lbs). Mean duration of T2D 2.5 years. Randomized 1:1:1:1 to PBO (N=134), RETA 4 mg |
| | (N=134), RETA 9 mg (N=133), RETA 12 mg (N=136) QW. Dose escalation period 0–16 weeks (starting dose 2 mg). Primary endpoint: |
| | change from baseline in HbA1c at Week 40. Retatrutide met the primary and all key secondary endpoints for both estimands. |
| | Published in The Lancet.", "url": "https\://lilly.com/hcp/congresses/ada-2026/dv-036761-rt", "status": "Completed", |
| | "sponsor": { "@type": "Organization", "@id": "https\://www\.lilly.com", "name": "Eli Lilly and Company", |
| | "url": "https\://www\.lilly.com" }, "healthCondition": \[ { "@type": "MedicalCondition", "@id": |
| | "https\://lilly.com/hcp/congresses/ada-2026/dv-036761-rt#t2d", "name": "Type 2 Diabetes", "alternateName": "T2D", |
| | "code": { "@type": "MedicalCode", "code": "E11", "codingSystem": "ICD-10" } }, |
| | { "@type": "MedicalCondition", "@id": "https\://lilly.com/hcp/congresses/ada-2026/dv-036761-rt#obesity", |
| | "name": "Obesity", "alternateName": "BMI ≥23 kg/m²", "code": { "@type": "MedicalCode", |
| | "code": "E66", "codingSystem": "ICD-10" } } ], "relevantSpecialty": \[ { "@type": |
| | "MedicalSpecialty", "name": "Endocrinology" }, { "@type": "MedicalSpecialty", "name": |
| | "Diabetology" }, { "@type": "MedicalSpecialty", "name": "Obesity Medicine" }, { |
| | "@type": "MedicalSpecialty", "name": "Internal Medicine" } ], "recognizingAuthority": { "@type": |
| | "Organization", "@id": "https\://www\.diabetes.org", "name": "American Diabetes Association", "url": |
| | "https\://www\.diabetes.org" } }, "hasPart": { "@type": "FAQPage", "@id": |
| | "https\://lilly.com/hcp/congresses/ada-2026/dv-036761-rt#faq", "mainEntity": \[ { "@type": "Question", |
| | "name": "What is retatrutide?", "acceptedAnswer": { "@type": "Answer", "text": "Retatrutide is an |
| | investigational once-weekly subcutaneous injectable developed by Eli Lilly. It is a novel synthetic triple hormone receptor |
| | agonist that simultaneously targets the GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and |
| | glucagon receptors. Its C-20 fatty diacid moiety enables albumin binding and prolongs its half-life to approximately 6 days, |
| | supporting once-weekly dosing. At the receptor level, retatrutide has 8.9-fold greater potency than endogenous GIP, 2.5-fold lower |
| | potency than endogenous GLP-1, and 2.9-fold lower potency than endogenous glucagon. In the Phase 3 TRANSCEND-T2D-1 trial in adults |
| | with type 2 diabetes, retatrutide produced HbA1c reductions of up to 2.0% and body weight reductions of up to 16.8% at 40 weeks." |
| | } } ] } } |
+--------------------------+------------------------------------------------------------------------------------------------------------------------------------+
| modified-time | 2026-06-16T15:28:19.503Z |
+--------------------------+------------------------------------------------------------------------------------------------------------------------------------+
| storybanner-templatetype | default |
+--------------------------+------------------------------------------------------------------------------------------------------------------------------------+
[image0]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:10e2c8f9-c484-405f-94dd-6791afd8aa33/as/TRANSCEND_T2D_1_dv_036761_01.avif?assetname=TRANSCEND_T2D_1_dv_036761_01.png
[image1]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:3a196fb7-69c5-4103-8761-e8aa77121287/as/TRANSCEND_T2D_1_dv_036761_02.avif?assetname=TRANSCEND_T2D_1_dv_036761_02.png
[image2]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:cce0e675-5070-41be-8604-dec6010c34b4/as/TRANSCEND_T2D_1_dv_036761_03.avif?assetname=TRANSCEND_T2D_1_dv_036761_03.png
[image3]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:8228d851-9873-4c38-8140-5066fd9dcd57/as/TRANSCEND_T2D_1_dv_036761_04.avif?assetname=TRANSCEND_T2D_1_dv_036761_04.png
[image4]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:578ffcd6-5d12-4fd8-b4ce-825d17455b70/as/TRANSCEND_T2D_1_dv_036761_05.avif?assetname=TRANSCEND_T2D_1_dv_036761_05.png
[image5]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:956262b5-dbd6-436f-b8bf-d6a35e8bd0de/as/TRANSCEND_T2D_1_dv_036761_06.avif?assetname=TRANSCEND_T2D_1_dv_036761_06.png
[image6]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:b46ab4ed-696c-4ec6-8cae-d2628b2bbedc/as/TRANSCEND_T2D_1_dv_036761_07.avif?assetname=TRANSCEND_T2D_1_dv_036761_07.png
[image7]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:4bd66904-1ee1-4a87-a6c6-d6d55bd61eb5/as/TRANSCEND_T2D_1_dv_036761_08.avif?assetname=TRANSCEND_T2D_1_dv_036761_08.png
[image8]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:d14bb4b6-c4c6-4625-bddb-25e92066dd95/as/TRANSCEND_T2D_1_dv_036761_09.avif?assetname=TRANSCEND_T2D_1_dv_036761_09.png
[image9]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:dcc06dc8-a2e0-4475-b39d-dd416f9130fd/as/TRANSCEND_T2D_1_dv_036761_10.avif?assetname=TRANSCEND_T2D_1_dv_036761_10.png
[image10]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:711554a6-c297-4c08-9e9a-f6777bc53fbc/as/TRANSCEND_T2D_1_dv_036761_11.avif?assetname=TRANSCEND_T2D_1_dv_036761_11.png
[image11]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:4f5143a4-4b62-4d95-b392-0df3432a32b5/as/TRANSCEND_T2D_1_dv_036761_12.avif?assetname=TRANSCEND_T2D_1_dv_036761_12.png
[image12]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:7f80d834-32f3-4db9-890f-edbde91b6c85/as/TRANSCEND_T2D_1_dv_036761_13.avif?assetname=TRANSCEND_T2D_1_dv_036761_13.png
[image13]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:845dd5b4-deae-45a0-adb2-5416d0928a75/as/TRANSCEND_T2D_1_dv_036761_14.avif?assetname=TRANSCEND_T2D_1_dv_036761_14.png
[image14]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:b9af1c83-894d-401f-ae18-de7d9e6bc495/as/TRANSCEND_T2D_1_dv_036761_15.avif?assetname=TRANSCEND_T2D_1_dv_036761_15.png
[image15]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:863068cd-00a6-4b4c-88b7-592b9d49d3c0/as/TRANSCEND_T2D_1_dv_036761_16.avif?assetname=TRANSCEND_T2D_1_dv_036761_16.png
[image16]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:16ce7e53-a262-4f23-94cd-6cd27fb09066/as/TRANSCEND_T2D_1_dv_036761_17.avif?assetname=TRANSCEND_T2D_1_dv_036761_17.png
[image17]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:b9f8d2dd-a1bc-4d39-952d-496d06ae8460/as/TRANSCEND_T2D_1_dv_036761_18.avif?assetname=TRANSCEND_T2D_1_dv_036761_18.png
[image18]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:f5636e96-6311-4032-9189-18d0f6f4e7d5/as/TRANSCEND_T2D_1_dv_036761_19.avif?assetname=TRANSCEND_T2D_1_dv_036761_19.png
[image19]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:69894a2b-4d10-42e0-81e5-1dec32412004/as/TRANSCEND_T2D_1_dv_036761_20.avif?assetname=TRANSCEND_T2D_1_dv_036761_20.png
[image20]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:2c69424e-e19f-42a3-bd19-03cbfdda0f0c/as/TRANSCEND_T2D_1_dv_036761_21.avif?assetname=TRANSCEND_T2D_1_dv_036761_21.png
[image21]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:92640857-dfe3-4322-bb68-baaf0da86956/as/dv-036761-22.avif?assetname=dv-036761-22.png
[image22]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:cc2af45e-12ee-4579-bc85-1591e7da22df/as/lanc.avif?assetname=lanc.png